IT1400311B1 - Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. - Google Patents

Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.

Info

Publication number
IT1400311B1
IT1400311B1 ITRM2010A000232A ITRM20100232A IT1400311B1 IT 1400311 B1 IT1400311 B1 IT 1400311B1 IT RM2010A000232 A ITRM2010A000232 A IT RM2010A000232A IT RM20100232 A ITRM20100232 A IT RM20100232A IT 1400311 B1 IT1400311 B1 IT 1400311B1
Authority
IT
Italy
Prior art keywords
angiotensin
antagonists
inhibitors
receptor
association
Prior art date
Application number
ITRM2010A000232A
Other languages
English (en)
Inventor
Francesco Melani
Sandro Giuliani
Carlo Alberto Maggi
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1400311(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Priority to ITRM2010A000232A priority Critical patent/IT1400311B1/it
Priority to NZ603414A priority patent/NZ603414A/en
Priority to MA35430A priority patent/MA34297B1/fr
Priority to CA2798573A priority patent/CA2798573A1/en
Priority to ARP110101590A priority patent/AR081376A1/es
Priority to PE2012002151A priority patent/PE20130812A1/es
Priority to JP2013509533A priority patent/JP2013526503A/ja
Priority to KR1020127032188A priority patent/KR20130101447A/ko
Priority to EA201201528A priority patent/EA201201528A1/ru
Priority to MX2012013054A priority patent/MX2012013054A/es
Priority to BR112012028887A priority patent/BR112012028887A2/pt
Priority to US13/697,066 priority patent/US20130131128A1/en
Priority to SG2012082319A priority patent/SG185474A1/en
Priority to EP11718734.4A priority patent/EP2568982B1/en
Priority to CN2011800232573A priority patent/CN103037861A/zh
Priority to TW100116119A priority patent/TW201206432A/zh
Priority to PCT/EP2011/057438 priority patent/WO2011141431A1/en
Priority to AU2011252151A priority patent/AU2011252151A1/en
Publication of ITRM20100232A1 publication Critical patent/ITRM20100232A1/it
Priority to IL222927A priority patent/IL222927A0/en
Priority to CL2012003143A priority patent/CL2012003143A1/es
Priority to ZA2012/09295A priority patent/ZA201209295B/en
Priority to ECSP12012332 priority patent/ECSP12012332A/es
Priority to CO12223245A priority patent/CO6640306A2/es
Priority to ECSP12012331 priority patent/ECSP12012331A/es
Publication of IT1400311B1 publication Critical patent/IT1400311B1/it
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITRM2010A000232A 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. IT1400311B1 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
SG2012082319A SG185474A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
CN2011800232573A CN103037861A (zh) 2010-05-10 2011-05-09 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途
CA2798573A CA2798573A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
ARP110101590A AR081376A1 (es) 2010-05-10 2011-05-09 Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
PE2012002151A PE20130812A1 (es) 2010-05-10 2011-05-09 Combinacion de inhibidor de xantina oxidasa y antagonistas del receptor de angiotensina ii
JP2013509533A JP2013526503A (ja) 2010-05-10 2011-05-09 キサンチンオキシダーゼ阻害剤とアンジオテンシンｉｉ受容体アンタゴニストとの合剤およびその使用
KR1020127032188A KR20130101447A (ko) 2010-05-10 2011-05-09 크산틴 옥시다아제 억제제 및 안지오텐신 ⅱ 수용체 길항제 및 이의 용도
EA201201528A EA201201528A1 (ru) 2010-05-10 2011-05-09 Комбинация ингибиторов ксантиноксидазы и антагонистов рецепторов ангиотензина-ii и ее применение
MX2012013054A MX2012013054A (es) 2010-05-10 2011-05-09 Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso.
BR112012028887A BR112012028887A2 (pt) 2010-05-10 2011-05-09 associação de inibidores de xantina oxidase e antagonistas receptores de angiotensina ii e uso dos mesmos
US13/697,066 US20130131128A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
NZ603414A NZ603414A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
EP11718734.4A EP2568982B1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
MA35430A MA34297B1 (fr) 2010-05-10 2011-05-09 Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation
TW100116119A TW201206432A (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
PCT/EP2011/057438 WO2011141431A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
AU2011252151A AU2011252151A1 (en) 2010-05-10 2011-05-09 Association of xanthine oxidase inhibitors and angiotensin II receptor antagonists and use thereof
IL222927A IL222927A0 (en) 2010-05-10 2012-11-08 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
CL2012003143A CL2012003143A1 (es) 2010-05-10 2012-11-08 Una combinacion de a) un inhibidor de la xantina oxidasa, febuxostat y b) al menos un antagonista del receptor de angiotensina ii, el cual es olmesartan medoxomil; composicion farmaceutica que los comprende; metodo de preparacion; y uso para tratar la hipertension, sola o asociada con hiperuricemia.
ZA2012/09295A ZA201209295B (en) 2010-05-10 2012-12-07 Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
ECSP12012332 ECSP12012332A (es) 2010-05-10 2012-12-10 Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
CO12223245A CO6640306A2 (es) 2010-05-10 2012-12-10 Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
ECSP12012331 ECSP12012331A (es) 2010-05-10 2012-12-10 Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.

Publications (2)

Publication Number Publication Date
ITRM20100232A1 ITRM20100232A1 (it) 2011-11-11
IT1400311B1 true IT1400311B1 (it) 2013-05-24

Family

ID=42753377

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.

Country Status (23)

Country Link
US (1) US20130131128A1 (it)
EP (1) EP2568982B1 (it)
JP (1) JP2013526503A (it)
KR (1) KR20130101447A (it)
CN (1) CN103037861A (it)
AR (1) AR081376A1 (it)
AU (1) AU2011252151A1 (it)
BR (1) BR112012028887A2 (it)
CA (1) CA2798573A1 (it)
CL (1) CL2012003143A1 (it)
CO (1) CO6640306A2 (it)
EA (1) EA201201528A1 (it)
EC (2) ECSP12012331A (it)
IL (1) IL222927A0 (it)
IT (1) IT1400311B1 (it)
MA (1) MA34297B1 (it)
MX (1) MX2012013054A (it)
NZ (1) NZ603414A (it)
PE (1) PE20130812A1 (it)
SG (1) SG185474A1 (it)
TW (1) TW201206432A (it)
WO (1) WO2011141431A1 (it)
ZA (1) ZA201209295B (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028371B1 (fr) * 2014-11-06 2016-11-18 Bull Sas Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede
KR102284764B1 (ko) 2020-07-08 2021-08-04 주식회사 우드메탈 멀티빔구조를 통한 부속의 결속이 용이한 칸막이

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
EP1020454B2 (en) 1998-06-19 2013-01-23 Teijin Pharma Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
EP1336407B1 (en) 2000-11-21 2006-05-03 Sankyo Company, Limited Composition containing an angiotensin ii receptor antagonist and a diuretic and its use for the treatment of hypertension
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
JP5242393B2 (ja) * 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법

Also Published As

Publication number Publication date
JP2013526503A (ja) 2013-06-24
IL222927A0 (en) 2012-12-31
EA201201528A1 (ru) 2013-04-30
AU2011252151A1 (en) 2012-11-29
EP2568982A1 (en) 2013-03-20
EP2568982B1 (en) 2014-04-02
ITRM20100232A1 (it) 2011-11-11
TW201206432A (en) 2012-02-16
KR20130101447A (ko) 2013-09-13
PE20130812A1 (es) 2013-08-08
BR112012028887A2 (pt) 2016-07-26
MX2012013054A (es) 2013-03-05
MA34297B1 (fr) 2013-06-01
US20130131128A1 (en) 2013-05-23
SG185474A1 (en) 2012-12-28
ECSP12012331A (es) 2013-02-28
AR081376A1 (es) 2012-08-29
CN103037861A (zh) 2013-04-10
CO6640306A2 (es) 2013-03-22
ZA201209295B (en) 2013-08-28
CA2798573A1 (en) 2011-11-17
ECSP12012332A (es) 2013-02-28
CL2012003143A1 (es) 2013-06-21
NZ603414A (en) 2014-03-28
WO2011141431A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
SMT201600098B (it) Antagonisti del complemento e loro usi
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
SMT201600078B (it) Antagonista del recettore per cgrp
HK1151218A1 (en) Notch-binding agents and antagonists and methods of use thereof notch-
ECSP12012034A (es) Antagonistas de pcsk9
EA200870409A1 (ru) Антагонисты киназы pi3
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
SMT201400114B (it) Derivati di 2-arilimidazolo come inibitori dell'enzima pde10a
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
BRPI1012097A2 (pt) antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos.
MA34075B1 (fr) Composition pharmaceutique comprenant un dérivé pyrimidineone
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
SMT201500296B (it) Antagonisti del recettore trpm8
CL2008001795A1 (es) Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
BRPI1009257A2 (pt) antagonista receptor de mineralocorticoide e métodos de uso.
DK2287163T3 (da) 2-amino-3-sulfonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidinantagonister af serotonin 5-ht6-receptorer, fremgangsmåder til fremstillingen og anvendelse deraf
IT1400311B1 (it) Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
BRPI0923878A2 (pt) Inibidores de giyt1 bicíclicos 3.1.0 e métodos de produção e uso dos mesmos.